15th Annual Indy Hematology Review

Saturday, March 10, 2018
JW Marriott Indianapolis
10 S. West Street
Indianapolis, IN

Presented by:
Community Health Network

Organized by:
Indy Hematology Education, Inc.

This Symposium is approved for 8.5 AMA PRA Category 1 Credit(s)™ by the Indiana Association of Pathologists, 7.75 CNE contact hours by the Ohio Nurses Association, and 7.75 CPE contact hours by the Purdue University College of Pharmacy
Gain knowledge that will immediately impact your practice. This full-day symposium features the nation's top experts in the field, comprehensive clinical content, the latest clinical research, and opportunities to interact with colleagues and vendors in an intimate group setting.

**A full day of presentations by today's leaders in Hematology and Hematologic Malignancies**

Accredited by the Indiana Association of Pathologists, this CME program has been designed to include content pertinent to the entire cancer care team; including hematologists and oncologists, physician assistants, nurse practitioners, nurses, pharmacists, researchers, and other healthcare professionals.

The program features highly intensive sessions that showcase each speaker's evidence-based treatment approaches, present cutting-edge scientific data that can be translated into new strategies for diagnosis and treatment, and addresses challenging patient care questions.

**Dive deeper into new advances and targeted treatments for:**
- Chronic and Acute Leukemias
- Indolent Lymphomas and aggressive non-Hodgkin's Lymphomas
- Hodgkin's Lymphoma
- Multiple Myeloma
- Myeloproliferative neoplasms
- Myelodysplastic syndromes
- Hematopoietic Stem Cell Transplantation
- Benign and non-benign hematology

After participating in dynamic discussions with both experienced faculty and peers, you'll leave this symposium with the resources and knowledge on how to use these innovative therapies as well as the experts' insights to help you provide optimal patient care.
Indy Hematology Education, Inc. is a 501(c), non-profit corporation, incorporated on February 15, 2010, in the State of Indiana, with the following purposes:

(a) Raise awareness and provide education regarding hematology and oncology diseases and disorders

(b) To encourage youth to pursue careers in hematology and oncology and

(c) To connect individuals suffering from or affected by hematology and oncology diseases and disorders to organizations, programs and service providers.

Register online: www.indyhematologyreview.com
7:00 AM - 2:30 PM – Registration

7:00 AM - 5:00 PM – Exhibit displays

7:30 AM – Breakfast: Product Theaters

8:30 AM – State of the Art: Treatments, Targets, and Diagnosis
Ruemu E. Birhiray, MD – Chair
CEO, Indy Hematology Education Inc.
Associate Professor of Clinical Medicine, Marian University of Osteopathic Medicine
Partner and Vice President, Hematology Oncology of Indiana, PC (Indianapolis, IN)

9:00 AM – Multiple Myeloma: Emerging Therapies
Kenneth Anderson, MD
Kraft Family Professor of Medicine, Harvard Medical School
Program Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (Boston, MA)

9:30 AM – Multiple Myeloma: What I recommend and how you should treat
Paul Richardson, MD
R.J. Corman Professor of Medicine, Harvard Medical School
Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (Boston, MA)

10:00 AM – Waldenström's Macroglobulinemia: Emerging options and current treatment paradigms
Steven Treon, MD, MA, PhD
Associate Professor of Medicine, Harvard Medical School
Senior Attending Physician for Medical Oncology at DFCI and Brigham & Women's Hospital
Director of the Bing Center for Waldenström's Macroglobulinemia
Dana-Farber Cancer Institute (Boston, MA)

10:30 AM – Break with Q & A

10:45 AM – Not so Benign Hematology
Robert Brodsky, MD
Director of Division of Hematology
Johns Hopkins Family Professor of Medicine and Oncology
Johns Hopkins University School of Medicine (Baltimore, MD)

11:15 AM – Benign Hematology: Coagulopathies and Beyond
Craig Kessler, MD
Professor of Medicine and Pathology
Director of Clinical Coagulation Laboratory in Division of Laboratory Medicine
Lombardi Comprehensive Cancer Center
MedStar Georgetown University Hospital (Washington, DC)

11:45 AM – Indolent Lymphomas and Hodgkin's Lymphoma: My treatment and emerging strategies
Bruce Cheson, MD, FACP, FAAS, FASCO
Deputy Chief of Division of Hematology and Oncology
Head of Hematology and Professor of Medicine
Lombardi Comprehensive Cancer Center
MedStar Georgetown University Hospital (Washington, DC)

12:15 PM – Aggressive B and T Cell Lymphomas: Treatment Paradigms in 2018
John Leonard, MD
Attending Physician, New York-Presbyterian Hospital
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Associate Dean of Clinical Research and Interim Chair of Department of Medicine
Weill Cornell Medical College (New York, NY)

12:45 PM – Q & A

1:00 PM – Lunch: Product Theaters

2:00 PM – T. HOWARD LEE KEYNOTE LECTURE
Chronic Lymphocytic Leukemia: Targets, Treatments, and Resistance
Thomas Kipps, MD, PhD
Professor of Medicine
Deputy Director of Research Operations and Interim Director
UC San Diego Moores Cancer Center (San Diego, CA)

3:00 PM – Challenging Cases Presentation
Michael C. Wiemann, MD – Co-Chair
Providence Hospital/St. John Health
Senior VP, CMO (Warren, MI)
3:05 PM – Chronic Myeloid Leukemia  
Richard Larson, MD  
Professor of Medicine in Section of Hematology/Oncology, Director of Hematologic Malignancies Clinical Research Program  
University of Chicago Comprehensive Cancer Center (Chicago, IL)

3:35 PM – Beyond JAK 2: Mastocytosis, CMML, Eosinophilic and Neutrophilic Leukemia; Treatments, Paradigms, and Diagnosis  
Ayalew Tefferi, MD, PhD  
Professor of Hematology and Internal Medicine  
Mayo Clinic (Rochester, MN)

4:05 PM – Myeloproliferative Neoplasms: What about JAK? PV, ET, MF  
John Mascarenhas, MD, MS  
Associate Professor of Medicine for Myeloproliferative Disorders Program  
Tisch Cancer Institute, Icahn School of Medicine  
Mount Sinai Medical Center (New York, NY)

4:35 PM – Break with Q & A

4:45 PM – Acute Myeloid Leukemias: Targets and Curability, So close but a journey so far  
Martin Tallman, MD  
Chief of Leukemia Service and Professor of Medicine  
Memorial Sloan-Kettering Cancer Center (New York, NY)

5:15 PM – Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: CARS, CARTS, Mechanics, and Beyond  
Elias Jabbour, MD, MA  
Associate Professor of Medicine, Department of Leukemia Section Chief of Acute Lymphocytic Leukemia  
The University of Texas MD Anderson Cancer Center (Houston, TX)

5:55 PM – Hematopoietic Stem Cell Transplantation: How I treat and when I transplant in 2018  
Richard Childs, MD, RADM, USPHS  
Senior Investigator for Laboratory of Transplantation Immunotherapy  
Clinical Director, National Heart, Lung, and Blood Institute (NHLBI)  
National Institutes of Health (Bethesda, MD)

6:30 PM – Wrap Up and Adjourn

Disclosure information, biographies, and slides (where authorized by the presenter) will be available at indyhematologyreview.com
REGISTRATION
To register online, go to indyhematologyreview.com and click on “Register.”

<table>
<thead>
<tr>
<th>Registration Type</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Early Bird Registration: ends February 2, 2018</strong></td>
<td></td>
</tr>
<tr>
<td>Early Bird Physicians</td>
<td>$175.00</td>
</tr>
<tr>
<td>Early Bird Physicians + CME Fee</td>
<td>$200.00</td>
</tr>
<tr>
<td>Early Bird Allied Health, Nurses, Pharmacists</td>
<td>$100.00</td>
</tr>
<tr>
<td>Early Bird Allied Health &amp; Nurses + CME Fee</td>
<td>$125.00</td>
</tr>
<tr>
<td>Early Bird Pharmacists + CPE Fee</td>
<td>$150.00</td>
</tr>
<tr>
<td>Industry &amp; Exhibitors</td>
<td>$350.00</td>
</tr>
<tr>
<td><strong>Standard Registration: after February 2, 2018</strong></td>
<td></td>
</tr>
<tr>
<td>Physicians</td>
<td>$225.00</td>
</tr>
<tr>
<td>Physicians + CME Fee</td>
<td>$250.00</td>
</tr>
<tr>
<td>Allied Health, Nurses, Pharmacists</td>
<td>$150.00</td>
</tr>
<tr>
<td>Allied Health &amp; Nurses + CNE Fee</td>
<td>$175.00</td>
</tr>
<tr>
<td>Pharmacists + CPE Fee</td>
<td>$200.00</td>
</tr>
<tr>
<td>Industry &amp; Exhibitors</td>
<td>$350.00</td>
</tr>
<tr>
<td>Scholarships* for Nurses, Students, Residents, and Fellows</td>
<td>$25.00</td>
</tr>
</tbody>
</table>

*A limited number of scholarships are available on a first-come, first-served basis.

If you are registering clinicians in your office, ensure that you fill in the attendee's full name and correct e-mail address so that the post-event survey and continuing education credits are e-mailed to the attendee.

REFUND POLICY
Request a registration cancellation refund on or before March 1, 2018, to receive a Full Refund. After March 1, there is NO REFUND.

HOTEL RESERVATIONS
To make reservations online, go to indyhematologyreview.com and click on “Hotel/Parking.” You can call the JW Marriott Indianapolis directly at 317-860-5800 or toll free at 1-888-236-2427. Mention “Indy Hematology Review” for the discounted group rate of $186 plus tax (currently 17%). The block of discounted rooms will be released on Friday, February 16, 2018. Make your reservation early.

PARKING
Parking is available at the JW Marriott Indianapolis. 24-hour parking rates are currently: $43 on-site parking; $48 valet. *Rates are subject to change without notice.

QUESTIONS?
Please contact Erica Olivero, 317-713-1530, erica@conventionmanagers.com.
CONTINUING EDUCATION INFORMATION

PHYSICIANS AND PHYSICIAN ASSISTANTS

LEARNING OBJECTIVES
At the completion of this activity, participants should be able to:
• Discuss new emerging hematology therapies in general and for chronic Myeloid Leukemia, acute Promyelocytic and Myeloid Leukemia, and Myeloproliferative disorders.
• Recognize molecular diagnosis, targeted therapies, and resistance mechanisms of Waldenström's Macroglobulinemia to assist in disease recognition.
• Discuss the advancement of immune check point inhibitors within hematologic malignancies and updated treatment paradigms presented at the American Society of Hematology meeting in Atlanta, Georgia in December 2017.
• Identify new regimens for Hematopoietic Stem Cell transplantation and identification of transplant candidates.
• Review the advancement in benign hematology research.
• Review new treatment regimens in chronic Lymphocytic Leukemia.

CME ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Indiana Association of Pathologists and Indy Hematology Education, Inc. The Indiana Association of Pathologists is accredited by the Indiana State Medical Association to provide continuing medical education for physicians.

DESIGNATION STATEMENT
The Indiana Association of Pathologists designates this live activity for a maximum of 8.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE STATEMENT
In accordance with the ACCME Standards for Commercial Support, educational programs sponsored by the Indiana Association of Pathologists (IAP) must demonstrate balance, independence, objectivity and scientific rigor. Prior to the activity, all faculty, authors, editors and planning committee members participating in an IAP-sponsored activity are required to disclose to attendees any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

NOTE: While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.

NURSES

CNE ACCREDITATION STATEMENT
This continuing nursing education activity was approved by the Ohio Nurses Association (OBN-001-91), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Approval valid through 2019.

Assigned ONA #21199
This program is approved for 7.75 contact hours.

PHARMACISTS

CPE ACCREDITATION STATEMENT
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution.

Universal Activity Number (UAN): 0018-9999-18-001-L01-P
This program is approved for 7.75 contact hours (0.775 CEU’s).

PHARMACY LEARNING OBJECTIVES
At the completion of this activity, participants should be able to:
• Discuss new emerging hematology therapies in general and for chronic Myeloid Leukemia, acute Promyelocytic and Myeloid Leukemia, and Myeloproliferative disorders.
• Recognize molecular diagnosis, targeted therapies, and resistance of mechanisms of Waldenström's Macroglobulinemia to assist in disease recognition.
• Discuss the advancement of immune check point inhibitors within hematologic malignancies.
• Identify new regimens of Hematopoietic Stem Cell transplantation and identification of transplant candidates.
• Review the advancement in benign hematology research.

Register online: www.indyhematologyreview.com
15th Annual Indy Hematology Review
Saturday, March 10, 2018 | 7:00 am - 6:00 pm

Presented by:

Community Health Network